Medicine and Dentistry
Peripheral T-Cell Lymphoma
98%
Follicular Lymphoma
93%
Classical Hodgkin Lymphoma
88%
Diffuse Large B-Cell Lymphoma
86%
Overall Survival
79%
Hodgkin's Lymphoma
77%
Neoplasm
62%
Lymphoma
60%
Disease
59%
Cohort Analysis
55%
Rituximab
54%
Positron Emission Tomography-Computed Tomography
52%
Anaplastic Large Cell Lymphoma
52%
Progression Free Survival
46%
Diagnosis
46%
Epstein Barr Virus
44%
Posttransplant Lymphoproliferative Disease
32%
Biological Marker
30%
Hazard Ratio
28%
Biopsy
27%
Proteomics
25%
Anthracycline
24%
Maculopapular Rash
23%
Programmed Death 1 Receptor
23%
Multivariate Analysis
22%
Bleomycin
22%
NK T Cell Lymphoma
21%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Breast Implant
21%
Autologous Stem Cell Transplantation
21%
Ibrutinib
21%
Predictive Marker
21%
Myeloproliferative Neoplasm
21%
Malignant Neoplasm
21%
Cancer
20%
Immunohistochemistry
20%
Protein Expression
19%
T-Cell Lymphoma
19%
Proportional Hazards Model
18%
Non-Hodgkin Lymphoma
18%
Clinical Trial
17%
Etoposide
17%
Positron Emission Tomography
17%
Adverse Outcome
17%
Radiation Therapy
16%
Tissue Microarray
16%
Quality of Life
16%
Systemic Therapy
16%
T Cell
15%
Adriamycin Bleomycin Vinblastine Dacarbazine
14%
Immunology and Microbiology
B Cell
100%
Overall Survival
73%
Rituximab
54%
Progression Free Survival
47%
T Cell
41%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
32%
Epstein Barr Virus
31%
Programmed Death 1 Receptor
24%
Lymphoproliferative Disorders
24%
Lymphoma Cell
22%
Comorbidity
21%
Transplant Procedure
21%
Protein Expression
18%
Positron Emission Tomography
16%
Signal Transduction
13%
Lymphocyte Count
12%
CD8
11%
Arm
11%
Lymphocyte
11%
Peripheral T-Cell Lymphoma Not Otherwise Specified
10%
Chemosensitivity
10%
Aleutian Mink Disease Virus
10%
Galectin 1
10%
Kidney Transplantation
10%
Neutrophil
10%
Crohn's Disease
10%
Infliximab
10%
Natural Killer T Cell
10%
Tree
10%
Neutrophil Count
10%
Tissue Distribution
10%
Vasculotropin C
10%
Hemoglobin Blood Level
10%
Avelumab
10%
Life Expectancy
10%
Molecular Epidemiology
10%
CD163
10%
Cell Death
10%
Cell Survival
10%
CD44
10%
Leukocyte
10%
Autologous Stem Cell Transplantation
10%
Death Receptor
10%
Gene Mutation
10%
Programmed Death-Ligand 1
9%
Human Leukocyte Antigen
9%
Gene Expression
8%
Reed Sternberg Cell
8%
Epstein Barr Virus
7%
Cell Population
6%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
50%
Rituximab
42%
Chemotherapy
41%
Progression Free Survival
36%
Overall Survival
35%
Hodgkin Disease
34%
Classical Hodgkin Lymphoma
34%
Peripheral T Cell Lymphoma
32%
Bleomycin
29%
Anthracycline
26%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Pixantrone
21%
Monotherapy
21%
Cohort Study
21%
Lung Toxicity
21%
Remission
20%
Ibritumomab Tiuxetan
19%
Epstein-Barr Virus
18%
Etoposide
16%
Cardiotoxicity
15%
Disease
14%
Biological Marker
13%
Nonhodgkin Lymphoma
13%
Programmed Death 1 Receptor
13%
Lymphoma
13%
T Cell Lymphoma
13%
Alisertib
12%
Neoplasm
12%
Immunotherapy
11%
Doxorubicin
11%
Mantle Cell Lymphoma
10%
Styrene
10%
Programmed Cell Death
10%
Paraneoplastic Pemphigus
10%
Alemtuzumab
10%
Yttrium 90
10%
Zanolimumab
10%
Galectin 1
10%
Survival Rate
10%
Avelumab
10%
Comorbidity
10%
Growth Promotor
10%
Molecular Epidemiology
10%
Idiopathic Thrombocytopenic Purpura
10%
Isoniazid
10%
Virus DNA
10%
Azacitidine
10%
Randomized Clinical Trial
10%
Posttransplant Lymphoproliferative Disease
10%
Follicular Lymphoma
9%
